Empery Asset Management’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Empery Asset Management’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$186K	Buy	+237,943	New	+$499K	1.11%	22

Other funds holding CDAK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Empery Asset Management's CDAK Position: Q3 2022 in Review

Empery Asset Management opened a new position in Codiak BioSciences, Inc. Common Stock (CDAK) in Q3 2022: 237,943 shares worth $186K. The stake represents 1.11% of the portfolio and ranks #22 among its holdings.

48 funds tracked by Wall St. Rank hold CDAK as of Q3 2022.

Empery Asset Management held 237,943 shares of Codiak BioSciences, Inc. Common Stock worth $186K as of Q3 2022.
Codiak BioSciences, Inc. Common Stock was a new Empery Asset Management position in Q3 2022.
Codiak BioSciences, Inc. Common Stock made up 1.11% of Empery Asset Management's portfolio in Q3 2022, its #22 holding.
48 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q3 2022.

Based on Empery Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.